Cloots RH, Sankaranarayanan S, de Theije CC, Poynter ME, Terwindt E, van Dijk P, Hakvoort TB, Lamers WH, Köhler SE. Ablation of Arg1 in hematopoietic cells improves respiratory function of lung parenchyma, but not that of larger airways or inflammation in asthmatic mice. Am J Physiol Lung Cell Mol Physiol 305: L364-L376, 2013. First published July 5, 2013; doi:10.1152/ajplung.00341.2012.-Asthma is a chronic inflammatory disease of the small airways, with airway hyperresponsiveness (AHR) and inflammation as hallmarks. Recent studies suggest a role for arginase in asthma pathogenesis, possibly because arginine is the substrate for both arginase and NO synthase and because NO modulates bronchial tone and inflammation. Our objective was to investigate the importance of increased pulmonary arginase 1 expression on methacholine-induced AHR and lung inflammation in a mouse model of allergic asthma. Arginase 1 expression in the lung was ablated by crossing Arg1 fl/fl with Tie2Cre tg/Ϫ mice. Mice were sensitized and then challenged with ovalbumin. Lung function was measured with the Flexivent. Adaptive changes in gene expression, chemokine and cytokine secretion, and lung histology were quantified with quantitative PCR, ELISA, and immunohistochemistry. Arg1 deficiency did not affect the allergic response in lungs and large-airway resistance, but it improved peripheral lung function (tissue elastance and resistance) and attenuated adaptive increases in mRNA expression of arginine-catabolizing enzymes Arg2 and Nos2, arginine transporters Slc7a1 and Slc7a7, chemokines Ccl2 and Ccl11, cytokines Tnfa and Ifng, mucus-associated epithelial markers Clca3 and Muc5ac, and lung content of IL-13 and CCL11. However, expression of Il4, Il5, Il10, and Il13 mRNA; lung content of IL-4, IL-5, IL-10, TNF-␣, and IFN-␥ protein; and lung pathology were not affected. Correlation analysis showed that Arg1 ablation disturbed the coordinated pulmonary response to ovalbumin challenges, suggesting arginine (metabolite) dependence of this response. Arg1 ablation in the lung improved peripheral lung function and affected arginine metabolism but had little effect on airway inflammation. airway hyperresponsiveness; arginine; inflammation ALLERGIC ASTHMA IS A CHRONIC inflammatory disorder of the lung that is characterized by a reversible limitation of the airflow due to an allergic reaction in the airways with the characteristics of a T H 2-predominant airway inflammation. The airway inflammation is initiated by the binding of inhaled allergens to complementary IgEs on IgE receptor-bearing cells. Upon activation, these cells release histamine, cytokines, and proteases, resulting in the activation of the inflammatory cascade with lung infiltration of eosinophils and mononuclear cells. Increased mucus production, mucosal edema, and a disproportionate smooth-muscle contraction lead to airway hyperresponsiveness (AHR). As a result of the recurring inflammation, airway remodeling develops as a consequence of fibrosis and airway wall thickening (2, 3, 6, 36) .
ALLERGIC ASTHMA IS A CHRONIC inflammatory disorder of the lung that is characterized by a reversible limitation of the airflow due to an allergic reaction in the airways with the characteristics of a T H 2-predominant airway inflammation. The airway inflammation is initiated by the binding of inhaled allergens to complementary IgEs on IgE receptor-bearing cells. Upon activation, these cells release histamine, cytokines, and proteases, resulting in the activation of the inflammatory cascade with lung infiltration of eosinophils and mononuclear cells. Increased mucus production, mucosal edema, and a disproportionate smooth-muscle contraction lead to airway hyperresponsiveness (AHR). As a result of the recurring inflammation, airway remodeling develops as a consequence of fibrosis and airway wall thickening (2, 3, 6, 36) .
Recent studies in animal models and patients revealed a potential role for the arginine-catabolizing enzyme arginase in the pathogenesis of asthma (28, 53) . Arginase exists as two isoforms, arginase 1 and arginase 2. The expression of cytoplasmic arginase 1 and mitochondrial arginase 2 is undetectable in healthy mouse lungs but is strongly upregulated in mouse models of allergic asthma (50, 59) . Arginase 1 is only found in cells with the morphological characteristics of macrophages that are present in the inflammatory infiltrates of asthmatic lungs (50, 59) . Arginases catabolize L-arginine to urea and ornithine, but arginine is also the substrate for nitric oxide (NO) synthesis by NO synthase (NOS). A deficient NO production represents a key feature of AHR (36) , since NO modulates bronchial and vascular tone by inducing relaxation of smooth muscle cells. NOS enzymes have a higher affinity for arginine (K m : 2-20 M) than arginases (K m : 1-5 mM), but the V max of arginase is ϳ1,000-fold higher than that of NOS, which confers the capability for regional substrate depletion of arginine (56) .
The role of arginases in the development and symptoms of allergic asthma is still incompletely understood. We, therefore, examined the effects of Arg1 deletion in the lung on methacholine-induced AHR and lung inflammation in a mouse model of asthma. In rodents, extensive arginase 1 expression in the myeloid lineage of blood cells is confined to macrophages and dendritic cells (37) . For that reason, we generated cell-specific arginase 1 knockouts by flanking exon 4 of Arg1 with loxP sites and crossing Arg1 fl/fl mice with either LysMCre tg/Ϫ (9) or Tie2Cre tg/Ϫ mice (23) to delete Arg1 in myeloid cells (9) , or in all hematopoietic and endothelial cells (47) , respectively. We sensitized and then exposed these mice to ovalbumin to induce allergic asthma (26) and measured their responsiveness to increasing doses of methacholine. The adaptive changes in gene expression, chemokine and cytokine secretion, and lung histology were quantified. We report that selective Arg1 ablation improves peripheral lung function, without affecting lung inflammation.
MATERIALS AND METHODS

Plasmid construction and recombinant ES cell selection.
The mouse Arg1 gene is located on chromosome 10. Since deletion of exon 4 causes a frame shift, we targeted this exon. The targeting vector (17.515 kb; Fig. 1A ) consisted of Arg1 exons and introns 2 and 3 (4.6 kb) at the 5= end, a Neo-TK selection cassette flanked by frt sites (10) , exon 4 (160 bp) flanked by loxP sites (46) , introns 4 -7, exons 5-8, and a small fragment downstream of the gene (in total 4.3 kb) at the 3= end. The targeting construct was sequence verified with respect to exons, splice junctions, and recombinase-recognition sites; digested with AscI (introduced by PCR for cloning purposes); and purified by electrophoresis and electroelution. Twenty-five micrograms of the targeting fragment was electroporated into the mouse ES cell line E14IB10 (129/Ola). Selection with G418 (200 g/ml) was started 24 h after electroporation. Vector sequences that were left on either end of the targeting construct allowed a PCR-based negative screen against random integrations. Proper recombination of the 3= end was demonstrated with Southern blotting after Blp1 digestion (Fig. 1A ) and probing with a 300-bp external genomic fragment, and by long-distance PCR, using AccuTaq (Sigma), an Arg1-specific primer 3= outside the targeting construct and a loxP-specific primer (Fig. 1A) . Proper recombination of the 5= end was demonstrated by long-distance PCR, using AccuTaq, a 5= frt-specific primer, and an Arg1-specific primer 5= outside the targeting construct (Fig. 1A) . Exons and junctions of candidate ES clones were sequence verified by using those long-PCR products. After a "deep split" to ensure the presence of recombined ES clones only (the recombined 8.5-kb band in the initial isolate was much less intense than the endogenous 6.1 kb band), the Neo-TK cassette was removed by transient transfection with an FLPe recombinase expression vector (kindly provided by Dr. The Frt-flanked Neo-TK selection cassette in intron 3, floxed exon 4, and the positions of relevant restriction enzymes are indicated. Blp1 was used to differentiate the recombined allele (8.5 kb) from the wild-type allele (6.1 kb; right Southern blot); Sbf1 and SpeI, both introduced during cloning, were used to demonstrate a 1:1 ratio between the recombined (8.3 kb) and wild-type (13.3 kb) Arg1 alleles in the blastocyst-injected ES cells (left Southern blot). The 3= 300-bp DNA fragment used as Southern probe is shown as a white box. The products of the 5= and 3= long-distance PCRs (4.65 and 4.27 kb, respectively), used to validate the sequence of the recombined allele, are shown in between the Southern blots. Note that in the picture of the 5= PCR 3 empty lanes were removed between the marker lane and the lane with the 5= PCR product. B: reduced arginase 1 protein levels in the lungs of ovalbumin (OVA)/OVA-treated Arg1-KO LysM (n ϭ 9) or Arg1-KO Tie2 mice (n ϭ 9), open bars, compared with the corresponding Arg1-Con mice (solid bars). C: detail of arginase 1 expression in OVA/OVA-treated Arg1-Con lung. by PCR with primers LysM-F and LysM-R or Tie2-F and Tie2-R (Table 1) ], yielding 300-bp-or 510-bp-positive bands, respectively, for Cre-positive animals. Arg1-Con and Arg1-KO LysM were 75% C57BL/6J and 25% 129P2OlaHsd, whereas Arg1-Con and Arg1-KO Tie2 were 50% C57BL/6J, 25% 129P2OlaHsd, and 25% FVB. Antigen sensitization and challenge. Ten-week-old male Arg1-KO LysM mice or Arg1-KO Tie2 mice, and their Arg1-Con littermates were injected intraperitoneally on days 0 and 14 with 10 g of ovalbumin (OVA), grade V (Sigma-Aldrich, Zwijndrecht, The Netherlands) in a total volume of 100 l PBS, containing 1 mg/ml of AlOH3 (alum) as adjuvant (Imject Alum, Thermo Scientific, Rockford, IL). On days 21-27, mice were exposed daily for 30 min to 1% (wt/vol) aerosolized OVA in PBS in custom-made inhalation chambers. The experimental groups consisted of two to three mice per genotype and treatment and the experiments were repeated on at least three different time points. AHR was assessed 12 h after the last challenge (41) . Lung airway resistance RN, tissue elastance H, and tissue resistance G in response to inhaled aerosolized methacholine were measured by use of a Flexivent apparatus (Scireq, Montreal, Canada).
Airway hyperresponsiveness. Mice were anesthetized with pentobarbital sodium. A total dose of 120 mg/kg was administered per mouse. First 80 mg/kg was administered to induce anesthesia and 40 mg/kg ϳ30 min later to maintain anesthesia. An 18-gauge blunt needle was inserted into the trachea and connected to a mechanical small animal ventilator (FlexiVent, Scireq, Montreal, Canada). Mice were ventilated at 200 breaths/min with a delivered tidal volume of 0.25 ml against a positive end-expiratory pressure of 3 cmH2O applied by a water trap for 10 min before the experiment was started. Aerosolized methacholine (Sigma, Steinheim, Germany) challenges were performed by delivering successively 0, 3.1, 12.5, and 50 mg/ml methacholine in PBS. Following each methacholine challenge, ventilation was interrupted every 10 s to allow for 1-s passive expiration followed by 2-s broad-band (1-19.6 Hz) volume perturbation. The peak-to-peak excursion of the ventilator piston during delivery of these perturbations was 0.17 ml, resulting in a delivery of ϳ0.14 ml after correcting for gas compression in the ventilator cylinder and connecting tubing. Pressure and flow were recorded during application of the perturbations and used to calculate the input impedance (Zrs) of the respiratory system. Zrs was then fitted to the uniformly ventilated model of the lung with constant-phase tissue impedance (12, 16) .
RN is the Newtonian resistance composed mostly of the flow resistance of the conducting pulmonary airways; I aw is the inertance of the gas in the central airways; H, also known as elastance, reflects the elastic energy stored in the tissues; G, also known as tissue resistance, reflects viscous dissipation of energy in the respiratory tissues as well as airflow heterogeneity; f is frequency; i ϭ ͌Ϫ1; and ␣ couples G and H. R N, G, and H all have units of cmH2O·s·ml Ϫ1 . RN and G are shown as maximal resistance and tissue damping after application of the methacholine challenge, whereas H is shown as the plateau value of the elastance following the initial peak response after the methacholine challenge.
Plasma collection and analysis. At the end of the experiment, blood was collected from the inferior caval vein in heparin-coated tubes, centrifuged for 3 min at 5,000 g, snap frozen in liquid nitrogen, and stored at Ϫ80°C. Plasma OVA-specific IgE levels were deter- (27) . After washing, sections were incubated with a 1:200 diluted biotinylated rabbit anti-rat secondary antibody (DAKO) for 45 min at RT. Sections were washed, incubated with streptavidin/horseradish peroxidase (HRP; Vector) for 30 min at RT and developed with 3,3=-diaminobenzidine (Sigma, Steinheim, Germany) for 10 min. Sections stained for arginase 1 and 2 were incubated with an AP-labeled secondary antibody (1:200, Sigma A-3687) for 45 min, developed for 30 min with nitrobluetetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Roche, Almere, The Netherlands), dissolved in 50 mM MgSO 4, 100 mM Tris·HCl (pH 9.5), and coverslipped with an aqueous mounting medium (DAKO).
Histological assessment. The H&E-stained slides were used to identify inflammation in general. Sirius red-and silver nitrate-stained slides, which visualize collagen and reticular fibers, respectively, were used to assess tissue remodeling in the lungs of OVA/OVA-treated mice. MBP-, MPO-, and ARG2-positive cells in full-face sections of the lung were imaged with a panoramic 3DHISTECH slide scanner and counted with 3DHISTECH software (3DHISTECH, Budapest, 
Hungary). Detection limits were set to count cells positive for diaminobenzidine with a diameter between 10 and 15 m. The density of cells is expressed per mm 2 . Milliplex assay. Tissue powder was homogenized in PBS, pH 7.6, in the presence of a proteinase inhibitor cocktail (Complete, Roche). Cytokines [CCL11 (a.k.a. eotaxin-1), IL-4, IL-5, IL-10, IL-13, TNF-␣, and IFN-␥] were quantified by using a Luminex xMAP multiplex platform, combined with a customized Milliplex mouse chemokine/cytokine panel from Millipore (Billerica, MA).
RNA isolation and quantification. Tissue powder was homogenized in Tri reagent (Sigma) with the Mini Bead-Beater (Biospec Products, Bartlesville, OK). To remove genomic DNA, RNA was precipitated with 2 M LiCl for at least 30 min at Ϫ20°C. RNA integrity was checked by denaturing gel electrophoresis. RNA concentration was determined with a NanoDrop-ND-1000 spectrophotometer at 260 nm (Isogen Life Sciences, Wilmington, DE), and 400 ng of total RNA was transcribed using a first-strand synthesis kit (Roche). Quantitative PCR was performed in a Lightcycler 480 (Roche), using Lightcycler 480 SYBRgreen Master Mix (Roche) and the following settings: denaturation 30 s at 95°C, annealing 30 s at 60°C, elongation 30 s at 72°C, 45 cycles, and a final elongation step for 5 min at 72°C. If reverse transcriptase was omitted, no product was formed. Primary fluorescent data were exported and analyzed with the Lin-Reg Analysis program (44) . mRNA abundance was expressed relative to 18S rRNA abundance. Primer sequences are given in Table 1 .
Western blot. Tissue powder was homogenized in RIPA buffer [25 mM Tris·HCl (pH 7.6), 150 mM NaCl, 1% Nonidet P-40, 1% Na-deoxycholate, 0.1% SDS, containing Complete cocktail (Roche)]. Protein concentration was measured with the bicinchoninic-acid assay (Pierce, Rockford, IL). Twenty-five micrograms protein was separated on an SDS-polyacrylamide gel, transferred onto 0.45 m nitrocellulose membranes by use of a wet transfer system (Bio-Rad, Hercules, CA), stained with Ponceau S to confirm equal loading of lanes, washed with TBS (50 mM Tris, 150 mM NaCl, pH 7.6), and blocked with 5% skimmed milk in TBS/0.5% Tween-2. Pearson's bivariate two-tailed correlation coefficients between each of the lung function parameters, mRNA and protein concentrations, histology scores, and plasma amino-acid concentrations were determined after combining the data from the comparable PBS/OVA and OVA/OVA groups. In Fig. 9 , P values of the resulting correlation coefficients were color coded, with red indicating a P Ͻ 0.001, orange 0.01 Ͼ P Ͼ 0.001, and yellow 0.05 Ͼ P Ͼ 0.01.
RESULTS
Generation of conditionally Arg1-deficient mice. We flanked exon 4 with loxP sites to create a conditionally Arg1-deficient mouse. When these Arg1 fl/fl mice were crossed with deleterCre females (48) to delete exon 4 in the germ line, the resulting Arg1 Ϫ/Ϫ mice died between postnatal days 10 and 14, as reported for constitutive Arg1-deficient mice (20) . At postnatal day 8, plasma levels of arginine and glutamine were approximately nine-and approximately twofold higher, respectively, whereas lysine levels were decreased to ϳ50% in Arg1
DelCre ) compared with Arg1 ϩ/fl (wild-type) mice (Table 2) . Although these changes, with the exception of the increased plasma arginine concentration, differ from those reported for Arg1-deficient mice in the moribund phase (20) , the data show unambiguously that excision of the floxed exon 4 results in a nonfunctional Arg1 allele.
Arginase expression in the lungs of asthmatic Arg1-Con and Arg1-KO mice. Half of the Arg1-KO LysM or Arg1-KO Tie2 mice and their Arg1-Con littermates were sensitized and then challenged with ovalbumin (OVA/OVA). The other 50% of the mice were only challenged with ovalbumin (PBS/OVA). In lungs of OVA/OVA-treated Arg1-Con mice, numerous peribronchiolar, parenchymal, and perivenous arginase 1-positive cells were found, whereas lungs of similarly treated Arg1-KO LysM mice showed fewer peribronchiolar ARG1-positive cells, while no ARG1-positive cells were found in lungs of OVA/OVA-treated Arg1-KO Tie2 mice (Fig. 1D ). Arginase 1 mRNA and protein were hardly detectable in the lungs of mice undergoing the PBS/OVA protocol, whereas a robust increase of arginase 1 mRNA and protein was found in the lungs of OVA/OVA-treated Arg1-Con mice (Figs. 1B and 2 ). The lungs of Arg1-KO LysM OVA/OVA mice contained residual arginase 1 mRNA and protein, but the expression of arginase 1 in the lungs of Arg1-KO Tie2 OVA/OVA mice did not exceed that seen in PBS/OVA mice (Figs. 1B and 2 ). Quantification showed that arginase 1 mRNA and protein concentrations in Arg1-KO LysM OVA/OVA lungs were reduced to 40 Ϯ 7 and 32 Ϯ 8%, respectively, of that found in Arg1-Con OVA/OVA mice, and in Arg1-KO Tie2 OVA/OVA mice to 4 Ϯ 2 and 2 Ϯ 0.2%, respectively, of that found in Arg1-Con OVA/OVA mice. Of note, we did not observe ARG1-positive endothelial cells in PBS/OVA or OVA/OVA-treated lung arteries (Fig.  1C) . Since the cell type specificity of the LysM-Cre and Tie2-Cre overlap with respect to Arg1-expressing cells, we conclude from these findings that the Arg1 allele was virtually completely deleted in the lungs of Arg1-KO Tie2 mice, including their macrophages, but incompletely in Arg1-KO LysM mice. Since the phenotype of Arg1-KO LysM mice was minimal, we limited the description of our study to Arg1-KO Tie2 mice and their Arg1-Con littermates.
Effect of Arg1 ablation on arginine-metabolizing and -transporting genes in lung and on circulating amino acids. We next investigated to what extent Arg1 ablation caused adaptive changes in the expression of arginine-metabolizing or -transporting proteins (Fig. 2) . Compared with PBS/OVA treatment, OVA/OVA induced increases in expression of Arg1, Arg2, Nos2, and Slc7a2 mRNA in the lungs of Arg1-Con mice, whereas the expression of Slc7a1 and Slc7a7 was not changed. In contrast, OVA/OVA treatment failed to induce an increase in expression of Arg1, Arg2, Nos2, and Slc7a2, and decreased that of Slc7a1 and Slc7a7 in Arg1-KO Tie2 mice. Furthermore, we evaluated the expression pattern of arginase 2 protein in sections of PBS/OVA and OVA/OVA-treated Arg1-Con and Arg1-KO Tie2 mice (Fig. 3) . As expected (59) arginase 2-positive cells with the morphology of macrophages accumulated in the lungs of OVA/OVA-treated mice. Quantification revealed a small increase in the number of ARG2-positive cells after OVA/OVA treatment, compared with PBS/OVA treatment, but no difference was detected between Arg1-Con and Arg1-KO Tie2 mice. Relative to PBS/OVA, OVA/OVA treatment caused a decrease in the concentration of circulating arginine and citrulline (Fig. 2) , and asparagine, serine, histidine, glycine, tyrosine, and methionine (Table 3) in Arg1-KO Tie2 mice, whereas that of glutamate increased. When OVA/OVA-treated Arg1-Con and Arg1-KO Tie2 mice were compared, the latter had lower concentrations of glycine, citrulline, and isoleucine (Table 3) .
Arg1 ablation improves peripheral lung function in OVA/ OVA-treated mice. To determine whether Arg1 ablation has an effect on respiratory mechanics, we measured responsiveness to inhaled methacholine (Fig. 4) . Compared with PBS/OVA, OVA/OVA treatment of Arg1-KO Tie2 and Arg1-Con mice resulted in an increase in R N upon exposure to methacholine (P Ͻ 0.04), albeit without difference between the Arg1-KO Tie2 and Arg1-Con mice. H, which was higher in OVA/OVA-than in PBS/OVA-treated Arg1-Con mice, was attenuated in OVA/ OVA-treated Arg1-KO Tie2 mice (P Ͻ 0.0009). Compared with PBS/OVA, OVA/OVA treatment also increased G in Arg1-Con and Arg1-KO Tie2 mice upon exposure to methacholine, but the response in Arg1-KO Tie2 mice was significantly lower (P Ͻ 0.001) than in Arg1-Con mice. In aggregate, these findings show that the absence of arginase 1 in the lung does not affect R N but does affect H and G, which reflect properties of the lung parenchyma rather than of the larger airways (12, 16) .
Arg1 ablation affects levels of mRNA and selected proteins of inflammatory genes in lung. We next investigated whether Arg1 ablation in the lung had an effect on the expression of asthma-associated cytokines (Fig. 5) . As expected, OVA/OVA treatment resulted in an increased abundance of Il4, Il13, Il5, Ccl11, Ccl2, and Il10 mRNAs in Arg1-Con mice. The OVA/ OVA-induced increase in Ccl11 expression was markedly reduced in Arg1-KO Tie2 mice. Furthermore, the expression of the inflammatory markers Tnfa and Ifng was strongly suppressed. The expression of the respiratory epithelium-specific Muc5ac and Clca3 genes was increased upon OVA/OVA treatment in both Arg1-Con and Arg1-KO animals, but the response was markedly attenuated in Arg1-KO Tie2 mice, in particular with respect to Clca3.
To investigate whether Arg1 deletion in the lung also affected the pulmonary protein concentration of cytokines and chemokines, we performed ELISAs for IL-4, IL-13, IL-5, CCL11 (eotaxin-1), IL-10, TNF-␣, and IFN-␥ on whole lung extracts (Fig. 6) . Except for IL-10 and IFN-␥, the pulmonary concentration of these proteins increased after OVA/OVA treatment, but the increase in IL-13 and CCL11 concentration was significantly lower in Arg1-KO Tie2 than in Arg1-Con mice. These data show that the production of most asthmaassociated cytokines proceeded independently of Arg1 deficiency in the lung.
Effect of Arg1 deletion on the production of OVA-specific IgE. OVA-specific IgE was undetectable in plasma of PBS/ OVA-treated mice but increased to easily detectable concentrations after OVA/OVA treatment in both wild-type and knockout mice, without significant differences between animals with or without Arg1 ablation (Fig. 6) . Apparently, ablation of Arg1 in Arg1-KO Tie2 mice did not affect the adaptive immune response to ovalbumin.
Effects of Arg1 deletion on tissue inflammation. Finally, we investigated whether Arg1 ablation in the lung modified the allergic asthma-induced inflammatory response of the lung (Fig. 7) . We did not observe any inflammatory cells in H&E-or ARG1-stained lung sections of PBS/OVA-treated mice (Fig.  7A, top row, and Fig. 1D ). Furthermore, there were no cells that contained MBP and MPO, which are markers for eosinophils and neutrophils, respectively (Fig. 7A, middle and bottom  rows) . In lungs of OVA/OVA-treated mice, on the other hand, many inflammatory cells were present, without discernible differences between Arg1-KO Tie2 mice and their Arg1-Con littermates. In lung sections stained for Sirius red and reticulin we found no differences between the OVA/OVA-treated Arg1-Con and Arg1-KO Tie2 mice in the amount of stained fibers (Fig. 8) . We quantified the number of MBP-and MPO-positive cells, and did not find differences between Arg1-KO Tie2 mice and their Arg1-Con littermates either (Fig. 7B) . Furthermore, lung sections stained for the presence of collagen and reticular fibers showed a similar degree of remodeling upon OVA/OVA treatment between Arg1-Con and Arg1-KO Tie2 mice (Fig. 8) . Apparently, Arg1 ablation in the lung does not affect the infiltration of inflammatory cells or tissue remodeling in response to experimental asthma, nor does it induce or reduce remodeling effects.
Comparison of the adaptive responses of Arg1-Con and Arg1-KO Tie2 mice. To answer the question whether arginase 1 activity exerted a coherent influence on the adaptive responses to asthma, we also investigated the correlation coefficients between each of the lung-function parameters, mRNA and protein concentrations, histology scores and plasma aminoacid concentrations (Fig. 9) . In Arg1-Con mice, lung function parameters H and G corresponded well mutually and with IL-5, IL-13, and CCL11. Except for Slc7a7, Slc7a1, Tnfa, and Ifng Relative to Arg1-Con mice, Arg1-KO Tie2 mice showed a pronounced general loss of correspondence of OVA/OVAsensitive parameters (Fig. 9) . A few correlations became stronger, such as that of H with Nos2 mRNA, IL-4 protein, and plasma citrulline concentrations and that of Arg1 mRNA with IL-4, IL-5, CCL11, and TNF-␣ protein concentrations. In aggregate, the data show that the near complete elimination of Arg1 expression from the lung disturbed the coordinated pulmonary response to OVA/OVA treatment, that is, showed that some aspect of arginine metabolism coordinated this response. 
DISCUSSION
We generated mice in which exon 4 of the Arg1 gene was floxed and effectively ablated arginase 1 expression in the lung by crossing them with Tie2Cre mice. Ablation of Arg1 in hematopoietic and endothelial cells did not affect OVA sensitization, as reflected in a similar increase in OVA-specific IgE in plasma of Arg1-Con and Arg1-KO mice. OVA sensitization and challenge of Arg1-KO mice did not affect R N but attenuated H and G, indicating that Arg1 ablation mainly affected the lung parenchyma. Furthermore, it reduced the mRNA abundance of Arg2, Slc7a1, Slc7a7, Ccl11, Tnfa and Clca3 in OVA/OVA-treated mice. Correlation analysis revealed that Arg1 ablation in the lung disturbed the coordinated pulmonary response to OVA/OVA treatment and made it more dependent on adaptive changes in arginine metabolism.
All our experiments were carried out in mice constructed in the 129Sv strain and backcrossed to the C57BL/6J strain. Since allergic asthma is considered a T H 2-dominated immune disorder, it is sometimes argued that the T H 1-responsive C57BL/6J mouse strain is less suitable to OVA sensitization and challenges than e.g., the T H 2-responsive BALB/c mouse strain. However, (nearly) all genetically modified mice are bred in the C57BL/6J strain. To avoid undue influence of the genetic background of the mice, we used Arg1
tg/Ϫ mice as reference throughout the study. Macrophages are the main myeloid-derived cells that express arginase upon induction by T H 2 cytokines in rodents (37) . Because no macrophage-selective Cre line exists, we used both LysMCre (9) and Tie2Cre (23) mice to bring about Arg1 ablation in macrophages. Whereas the expression of LysMCre is confined to macrophages and granulocytes (9) , that of Tie2Cre includes all hematopoietic and endothelial cells (47) . However, we found that the endothelium of lung arteries does not contain arginase 1, whereas, to the best of our knowledge, murine lymphocytes also do not express arginase. Furthermore, Tie2Cre-mediated ablation is usually complete (15, 23, 25, 47) , whereas LysMCre-mediated ablation is notably less effective, with target excision in 50 -80% of the target cells (9, 14, 21, 58) . In agreement with these earlier findings, we observed a much smaller reduction of arginase 1 protein in the lungs of OVA/OVA-treated Arg1-KO LysM mice (to ϳ30%) than in the lungs of similarly treated Arg1-KO Tie2 mice or in thioglycollate-elicited peritoneal macrophages of these mice (53) (to ϳ2%). Of interest, a recent study (9a) identified the ARG1-positive macrophages as CD11b Tie2 mice, therefore, shows that we did target arginase 1 expression in macrophages and that the present study allows conclusions with respect to the role of arginase 1 in allergic asthma of mice. Since the described phenotype was only observed in the Tie2 line, Arg1 deletion in macrophages apparently had to be near complete to mediate pronounced effects.
Arg1 ablation affects the expression of genes coding for arginine-metabolizing and -transporting proteins. The genetic elimination of Arg1 in macrophages of OVA/OVA-treated mice decreased the expression of Arg2, Slc7a1 (Cat1), and Slc7a7 (Lat1) mRNAs. These effects point to an arginase 1-dependent, and, hence, probably an arginine concentration-dependent decline in expression of genes involved in arginine transport and metabolism. The OVA/OVA-mediated increase in pulmonary arginase activity is reported to reduce parenchymal arginine content approximately twofold (22), but did not prevent an approximately twofold increase in NO production (4) .
Effect of Arg1 ablation on lung mechanics. R N in the large airways of OVA/OVA-treated Arg1-deficient mice was not different from that in similarly treated animals without the deletion, but H and G were markedly lower in the Arg-KO Tie2 mice. H and G primarily reflect peripheral lung function (1) and may, in allergic asthma, reflect "closure" of peripheral airways by mucous bridges (30, 31, 55) . In agreement, the mRNA abundance of Clca3 (Gob5), which regulates mucus production, and the mucin Muc5ac were lower in OVA/OVAtreated Arg1-KO Tie2 than Arg1-Con mice. Overexpression of Clca3 exacerbates AHR in OVA/OVA-treated mice, whereas downregulation attenuates peak airway pressure (resistance) after methacholine (29, 38) , strongly suggesting a role for this gene in the development of peripheral responsiveness. On the basis of our observations in sections stained for the presence of collagen and reticular fibers, the improved peripheral lung function could not be caused by less remodeling in OVA/OVA-treated Arg1-KO Tie2 mice compared with Arg1-Con mice. The effects of arginase 1 activity on the biomechanics of asthmatic lungs were also studied pharmacologically. Inhibitors of arginase activity decreased airway resistance in OVA/OVAtreated guinea pigs (33, 34) and mice, but did not change (19, 40) or even increased (7) H and G in mice. These pharmacological findings differ from the present findings in a genetic model and suggest that systemic and, in our case, macrophage-specific suppression of arginase activity has different effects. In fact, the presence or absence of arginase 1 in lung macrophages seems to be more important than its concentration, because the strong increase in Arg1 and Arg2 expression that was observed in OVA/OVA-treated Nos2-deficient mice compared with control (C57BL/6) mice (4) did not affect AHR (and eosinophil influx) (42) . On the basis of our findings in an OVA/OVA-treated arginine-deficient mouse model (our unpublished observations), we speculate that changes in the circulating concentration of arginine primarily affect the function of the larger airways, whereas the local presence or absence of arginase 1 primarily affects the function of the peripheral airways. This explanation C and F) . Note presence of additional reticular and collagen fibers in the cuff around main bronchi (b1) and arteries of OVA/OVA-treated mice, but the absence of such fibers around these structures in the parenchyma (b2). NOS2 was only found in the epithelium of bronchi that were not enveloped in connective-tissue sheaths. ap, Pulmonary artery; v, pulmonary vein.
would accommodate the observed differences between the pharmacological and genetic interventions.
Effect of Arg1 ablation in the lung on pulmonary inflammation. The allergic response to OVA challenge is at least partly mediated by OVA-specific IgE (49) . Unexpectedly, therefore, circulating anti-OVA IgE concentrations did not correlate with any other parameter of allergic asthma (Fig. 9) . OVA/OVA treatment resulted in a pan-pulmonary cellular inflammation in all mice, with participation of both eosinophils (MBP) and neutrophils (MPO). The relatively low number neutrophils relative to eosinophils in the lung of OVA/OVA-treated mice can be ascribed to our treatment protocol, as neutrophils preferentially infiltrate the lung shortly after a challenge (Ͻ24 h) and eosinophils later (43) . For the same reason, our relatively extended challenge protocol (6 consecutive days) probably accounts for the observation that only the number of eosinophils corresponded with the functional and biochemical sequels of OVA/OVA treatment (Fig. 9) . One or more of the inflammatory cell types produced and induced an increased expression of mRNAs of cytokines and chemokines that are involved in T H 2 responses (Il4, Il13, Il5, Ccl11), macrophage function (Ccl2, Il10), and mucus production in the respiratory epithelium (Muc5ac, Clca3). The expression of Muc5ac and Clca3 correlated well with the expression of genes coding for arginine-metabolizing and -transporting proteins in Arg1-Con mice, but this coordination was largely lost in Arg1-KO Tie2 mice, implying that cellular arginine concentration plays a role in their expression. In contrast, the abundance of Il4, Il13, Il5, Ccl2, and Ccl11 mRNA remained coordinated irrespective of the presence or absence of Arg1, implying no or a limited role of arginase 1. Arg1 deficiency in OVA/OVA-treated mice led to reduced Ccl11, Tnfa and Clca3 expression and CCL11 protein accumulation. The lower CCL11 (eotaxin-1) content, however, did not result in the recruitment (13) of fewer eosinophils to the lungs. Furthermore, the pulmonary content of IL-13, a cytokine associated with AHR induction (35), was reduced.
Posttranscriptional regulation of genes in OVA/OVA-treated mice. For arginase 1, IL-4, IL-13, IL-5, IL-10, CCL11, TNF-␣, and IFN-␥, we measured both mRNA and protein concentrations in lung homogenates. Correlations varying from reasonable (P Ͻ 0.05) to good (P Ͻ 0.01) were found between mRNA and protein levels in Arg1-Con animals for IL-4, IL-13, IL-5, and CCL11 (Fig. 9 ), but in Arg1-KO Tie2 mice, only mRNA and protein concentrations of IL-5 and CCL11 still correlated. Posttranscriptional control is well established for the expression of cytokines (8), but we were not aware of such extensive posttranscriptional regulation of Arg1 expression. Because we wanted to study the coordinated pulmonary response to ovalbumin sensitization and challenges in the pres- Fig. 9 . Correlation of lung function, abundance of pulmonary mRNAs and proteins, pulmonary histopathology, and concentrations of plasma amino acids in mice with lungs that are or are not Arg1 deficient. Top right triangle refers to data obtained in Arg1-Con mice and bottom left triangle to data from Arg1-KO Tie2 mice. Numbers show the correlation coefficients between parameters indicated above and to the left of the columns and rows, respectively, as measured in all 15 or 16 mice of the Arg1-Con or Arg1-KO Tie2 genotype studied, that is, both the PBS/OVA-and the OVA/OVA-treated groups. The significance of the correlations is color coded according to the P value of the correlation coefficient: yellow 0.05 Ͼ P Ͼ 0.01, orange 0.01 Ͼ P Ͼ 0.001, and red P Ͻ 0.001. Note the decline of the number or degree of significant correlations in Arg1-KO Tie2 compared with Arg1-Con mice, in particular with respect to lung function and abundance of pulmonary mRNAs and proteins.
ence or absence of arginase 1 enzyme activity, we have only determined changes in mRNA levels.
Comparison with other animal models with macrophagespecific Arg1 deletion. Recently, the effects of macrophagespecific Arg1 deficiency on lung function and inflammation were studied in OVA/OVA-treated wild-type mice after bone marrow transplantation with constitutively Arg1-deficient cells (39) , a procedure that also involves Arg1 elimination in all bone marrow-derived cells. Comparable to our results, infiltration of the lungs with eosinophils and neutrophils was similar in mice with or without Arg1 ablation in hematopoietic cells. Lung function was assessed with the airway pressuretime index, which is less sensitive to changes in peripheral lung function (45) and may explain why no differences in lung function were found in that study (39) .
The effects of arginase 1 activity on the biomechanics of asthmatic lungs were also studied with RNA interference and administration of arginase inhibitors. Inhibition of Arg1 expression by instilling anti-Arg1 shRNA in the trachea of mice attenuated IL-13-induced airway resistance (Raw) (57), whereas we found that genetic ablation did not have this effect. The discrepancy may be caused by the amount of rIL13 instilled into the lung (10 g), which exceeds the content of IL-13 in OVA/OVAtreated lungs (ϳ100 pg/mg lung protein) by three orders of magnitude. Pharmacological inhibition of arginase activity decreased R N in OVA/OVA-treated guinea pigs (32, 34) and mice (19, 40) but did not change H or G, although one mouse study found no change R N and an increase in H and G (7).
Both Nos1-and Nos3-deficient mice suffer from a more pronounced AHR than wild-type mice (17, 18) , whereas in Nos3-overexpressing mice, allergen-induced AHR to methacholine is completely abolished (11, 51) , indicating a prime role for NO in airway relaxation. In agreement, inhibition of arginase activity in OVA/OVA-treated Nos2 Ϫ/Ϫ mice did not induce AHR, suggesting that NOS1 and -3 used the increased tissue arginine levels to produce more NO and relax the smooth muscles of the larger airways (42) . Similarly, inhibition of NOS2 almost completely abolished OVA/OVA-induced AHR in BALB/c mice (24) . Since Nos2 overexpression also decreases airway resistance (Raw) (17a), the source of NO is apparently less important.
The use of strong arginase inhibitors like nor-NOHA increase tissue arginine levels and corresponding decreases in AHR and eosinophil influx in C57BL/6 mice (5, 39). In another series of experiments with arginine-rather than Arg1-deficient mice (our unpublished observations), we found that circulating arginine concentrations primarily affected R N in the larger airways. We, therefore, hypothesize that ablation of Arg1 in lung macrophages increases the parenchymal arginine concentration, which, in turn, facilitates NO production and smoothmuscle relaxation in the peripheral airways, but not the larger conducting airways.
Conclusion. Ablation of Arg1 in macrophages leads to an improvement of peripheral lung function in OVA/OVA-treated Arg1-KO Tie2 mice, without altering air hyperreactivity and lung inflammation.
